MicroRNAs (miRNAs) are small,~22 nucleotide long, noncoding single-stranded RNA molecules (He and Hannon, 2004) . It has been reported that miRNAs are expressed in all animal cells and have fundamental roles in cellular activities, such as development, cellular differentiation, proliferation, apoptosis, cell-cycle control, metabolism, and cancer (Friedman and Jones, 2009; Lagos-Quintana et al., 2003) . miRNAs can downregulate gene expression by affecting messenger RNA (mRNA) stability and influencing protein synthesis in a sequence-specific manner (Shah et al., 2010) . miRNA has also been implicated in gene expression activation by upregulation of target mRNA translation (Ma et al., 2010) . It is estimated that~60% of human mRNAs are regulated by miRNAs . Similar to mRNA, some miRNAs are produced in cell-or tissue-specific manners (Wang et al., 2009; Weber et al., 2010) . Recently, many reports concerning miRNAs related to cancer have been published and suggest that miRNAs may serve as a new kind of tissue-based marker for cancer classification and prognostication (Bartels and Tsongalis, 2009; Shah et al., 2010; Wei et al., 2010) .
Drug-induced liver injury is an adverse event that frequently leads to cessation of drug testing in clinical trials, restrictions on drug use, and the withdrawal of approved drugs (Fannin et al., 2010) . Existing biomarkers of liver injury (e.g., serum alanine and aspartate aminotransferases [ALT and AST] and bilirubin) provide reasonable indicators of damage or altered function (Shi et al., 2010) ; however, serum ALT and AST activities are known to be increased in other organ injuries (Kim et al., 2008; Nathwani et al., 2005) . New reliable biomarkers of liver injury are urgently required in the clinic and in preclinical pharmaceutical evaluation. It has been demonstrated that liver tissue or blood gene expression data can be used to classify hepatotoxicants (Heinloth et al., 2004; Lobenhofer et al., 2008) . The use of genomic approaches to discover novel biomarkers (mRNA and miRNA) of adverse effects is a new area of research receiving much attention (Mendrick, 2011) .
Previous studies have been carried out to evaluate the miRNA alterations in the liver following single doses of acetaminophen (APAP) or carbon tetrachloride (CCl 4 ) (Fukushima et al., 2007) . miR-298 and miR-370, which may be involved in the regulation of oxidative stress enzymes, are commonly affected by the two hepatotoxicants. In addition to analysis of target tissues, the use of body fluids for miRNA profiling is appealing for both preclinical and clinical use . Circulating miRNA has tremendous potential as a biomarker in the clinic because sample collection is relatively easy. It also benefits preclinical studies by allowing researchers to collect serial time points from an animal as opposed to collecting tissue at a single time point after sacrifice. Moreover, miRNAs are present in various extracellular body fluids in a remarkably stable form, which increases their potential for practical applications. Wang et al. (2009) have reported that miR-122 and miR-192 concentrations in mouse plasma increased earlier than the increase of ALT activities after APAP treatment. Another study also reported the increased plasma miR-122 in patients with chronic hepatitis B viral infection . The aims of this study were to find the commonly changed urinary miRNAs in response to hepatotoxicants and to investigate the correlation between urinary miRNA targets and gene expression profiles in the liver.
The two classical hepatotoxicants chosen in this study were APAP and CCl 4 , which cause acute hepatocellular necrosis following a single administration at a toxic dose. CCl 4 also causes other hepatic changes, such as lipid accumulation, which allowed a comparison of the differential effects of these two hepatotoxicants. The mechanism responsible for these two hepatotoxicants is well understood. The toxicity of APAP and CCl 4 require metabolic activation by cytochrome P450s (CYP1s) to active metabolites. The covalent binding of toxic metabolites to cell components is considered as the first step and leads to liver cell damage. Because CYP1 activity is higher in the centrilobular region of the liver, APAP and CCl 4 induce liver cell necrosis in this particular zone. Penicillin (PCN) is a widely used antibiotic. It was chosen as a negative control because it does not cause adverse effects in the liver, even at very high doses.
The analyses presented in this study demonstrate the utility of using urinary miRNA profiling as biomarkers of liver injury. Furthermore, the urinary miRNA profile reflects the perturbations of major cellular pathways in the liver. Linking urinary miRNA targets to the changes of liver gene expression provides new insight into the processes of liver injury.
MATERIALS AND METHODS
Chemicals. APAP, methylcellulose, CCl 4 , and corn oil were purchased from Sigma-Aldrich (St Louis, MO). Sodium chloride was purchased from Fisher (Pittsburgh, PA). Penicillin V Potassium Tablets were purchased from Teva Pharmaceuticals (Sellersville, PA) and were ground to a fine powder for dosing. TRIzol reagent was purchased from Invitrogen (Carlsbad, CA).
Animal care and study design. Six-to seven-week-old male SpragueDawley rats, provided by the U.S. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR) breeding colonies, were used for the study. Animal care was performed in accordance with the National Institutes of Health (NIH) ''Guide for the Care and Use of Laboratory Animals'' and was authorized by the NCTR Institutional Animal Care and Use Committee. After a 7-day acclimation period, rats were assigned to experimental groups by weight averaging and housed individually in polycarbonate cages using hardwood chip bedding. During the study, room temperatures remained within 19-23°C, and fluorescent lighting was provided on a 12 h on and 12 h off cycle. Filtered tap water was provided ad libitum, and NIH-41-irradiated diet was provided ad libitum except during designated periods of fasting.
APAP, CCl 4 , and PCN were administered as a single dose via oral gavage. For APAP, rats were fasted overnight for at least 12 h prior to dosing, with feed given back to the animals 4 h after dosing. The CCl 4 and PCN rats were administered feed ad libitum. For the APAP study, there were four rats in the 0.5% methylcellulose vehicle control group and seven rats in the APAP (1250 mg/kg) group (extra animals were included because high doses of APAP can result in lethality). For the CCl 4 study, there were five rats in the corn oil vehicle control group and five rats in the CCl 4 (2000 mg/kg) group. For the PCN study, there were five rats in the 0.5% methylcellulose vehicle control group and five rats in the PCN (2400 mg/kg) group. RNA samples from three animals spread among several groups were either not available or were not of high quality for reverse transcription (RT), leaving 28 samples for analysis with a minimum of four samples per group.
Urine sample collection and urinalysis. Rats were acclimated to metabolism cages for approximately 24 h prior to dosing and the start of urine collection. After dosing, the animals were returned to the metabolism cages, and urine was collected into 50 ml polypropylene containers over 24 h. The urine containers were surrounded by a frozen saltwater mixture during the collection period to prevent bacterial growth and sample degradation. This mixture quickly froze the urine in the collection tube and kept it frozen during the entire collection period. After thawing on ice, an aliquot was removed and subject to urinalysis for the following parameters: glucose, protein, bilirubin, ketones, urobilinogen, nitrites, blood, leukocytes, micro protein, urine creatinine, and urine glucose. The remaining urine was centrifuged at 10,000 3 g for 10 min at 4°C to pellet cellular debris and then aliquoted and frozen at À80°C.
Necropsy, clinical chemistry, and histopathology analysis. In this study, all rats survived until the planned necropsy date, and all blood and histopathology samples were collected approximately 24 h after dosing. Rats were anesthetized with carbon dioxide, blood was withdrawn via cardiac puncture, and the rats were then euthanized by carbon dioxide asphyxiation. Blood was collected into serum separator or ethylenediaminetetraacetic acid (EDTA) tubes (BD, Franklin Lakes, NJ). Blood in the serum separator tube was allowed to clot for 30-60 min at room temperature, centrifuged at 1000 3 g for approximately 10 min, and the serum was analyzed on an automated clinical chemistry analyzer (Alfa Wassermann Alera, West Caldwell, NJ) for creatinine, blood urea nitrogen, ALT, AST, alkaline phosphatase (ALP), gamma glutamyl transferase, glucose, cholesterol, triglycerides, chloride, sodium, potassium, calcium, phosphorus, albumin, total protein, and total bilirubin. Blood in the EDTA tube was analyzed the same day as collection on an ABX Pentra 60 Cþ analyzer (ABX, Irvine, CA) for red and white blood cell counts, hemoglobin, hematocrit, mean corpuscular hemoglobin concentration, mean corpuscular volume, platelets, and differential white blood cell count. A gross necropsy was conducted on all animals and included the examination of all major organs, body cavities, and external surfaces. The brain, heart, kidneys, liver, lung, and testes were weighed. Sections of the liver and kidneys were fixed in 10% neutral buffered formalin, routinely processed, embedded in paraffin, sectioned at 5 lm, stained with hematoxylin and eosin, and examined by light microscopy by a board-certified veterinary pathologist. Lesions were scored on a 5-point scale (0 ¼ normal, 1 ¼ minimal, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ marked). Serum ALT and AST data were analyzed using Student's t-test. Differences between groups were considered significant at p < 0.05. Serum ALT and AST values were log-transformed prior to statistical analysis.
RNA isolation. Total RNA was isolated from approximately 30 mg of liver using Qiagen RNeasy Mini Kit (Qiagen Inc., Valencia, CA) according to 336 the manufacturer's protocol. Total RNA concentrations were quantitated on a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE). The purity and quality of extracted RNA were evaluated using the RNA Nano Chips and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA samples with RNA integrity numbers greater than 8.0 were used for microarray analysis. Liver miRNAs were isolated from the same total RNA using mirVana miRNA Isolation Kit (Ambion) that specifically captures small RNAs with lengths of less than 200 nucleotides.
Total RNA from 300 ll urine was extracted using the TRIzol method according to the manufacturer's protocol. Briefly, 1 ml of TRIzol was added to 300 ll of urine. The sample was mixed and incubated for 5 min at room temperature, followed by the addition of 200 ll chloroform. After mixing vigorously for 15 s, the sample was centrifuged at 12,000 3 g at 4°C for 15 min. The upper aqueous phase was carefully transferred to a new tube, and 500 ll isopropanol was added to precipitate the RNA. The RNA pellet was cleaned in 1 ml 75% ethanol and redissolved in RNase-free water. Total RNA concentrations were quantitated on a NanoDrop spectrophotometer (NanoDrop Technologies). Qualitative analyses were performed on each sample using the Agilent small RNA kit on the Agilent 2100 Bioanalyzer (Agilent Technologies).
miRNA measurement by PCR arrays. Three hundred nanograms of urine or liver RNA was converted into complementary DNA (cDNA) using a RT 2 miRNA First Strand Kit (Qiagen/SABiosciences Corporation, Frederick, MD). All the synthesized cDNAs were mixed with 2 3 RT 2 SYBR Green PCR Master Mix (Qiagen/SABiosciences) and dispersed into a 384-well Rat Genome miRNA PCR Array (MAR-3100E, Qiagen/SABiosciences) with 10 ll/well reaction volume. In order to decrease the loading variance, all the cDNA mixes were loaded by a Beckman Coulter Biomek FX Liquid Handler (Beckman Coulter Inc., Brea, CA). The PCR array contained a panel of primer sets for 370 rat miRNAs, 4 blanks, 4 small RNAs as the internal controls, 3 reverse transcription controls (RTC), and 3 positive PCR controls (PPC). The real-time qRT-PCR was performed on a 7900 Real-Time PCR System (Applied Biosystems Inc., Foster, CA) with the following cycling parameters: 95°C for 10 min, then 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. SYBR Green fluorescence was recorded from every well during the annealing step of each cycle. The threshold cycle (Ct) value of each sample was calculated with SDS software 2.3 (Applied Biosystems). The baseline was automatically defined by the software, and the threshold line was set as 0.15 across all the plates. All the samples passed the quality controls based on the Ct values of RTC and PPC. Any Ct value less than 35 was considered a positive call.
miRNA data normalization and statistical analysis. Relative miRNA expression levels were determined with the DCt method, normalized with miR-193, miR-323*, and miR-675 and reported as 2 ÀDCt , where DCt ¼ Ct (miRNA of interest) À Ct (housekeeping). miR-193, miR-323*, and miR-675 were geometrically averaged (Vandesompele et al., 2002) as the ''housekeeping'' endogenous controls because these exhibited stable levels across the vehicle control and three treated groups. Liver miRNA levels were normalized to U6 snRNA. Fold change was calculated as: fold change ¼ 2 (downregulated in PCN group). The Student's t-test was used to calculate the p value to determine whether there was a significant difference for urinary miRNA levels between the control and the treated groups for each miRNA. Absolute fold changes of greater than twofold at p < 0.01 were considered significant. Hierarchical cluster and principal component analyses (HCA and PCA) were performed as described previously (Fang et al., 2009) . The normalized DCt values were used for these analyses.
Microarray data analysis. Liver gene expression studies (n ! 4 per group) were completed using single color (Cy3) Agilent Whole Rat Genome 4 3 44 K microarrays, which contain four identical arrays per slide, and reagents according to the manufacturer's protocols (Agilent Technologies, Santa Clara, CA). Microarray intensity data were uploaded to the ArrayTrack (free genomics analysis software available from the U.S. FDA NCTR) database and normalized using 75th-percentile scaling without background subtraction. Statistical analyses were performed on normalized intensity values using t-test with a p-value < 0.05 and an absolute fold-change value of 1.5 or greater. Less stringent criteria were used in the mRNA microarray analysis, when compared with the miRNA PCR data, because the prediction of mRNA targets of miRNA are mostly based on computer algorithms and are not completely accurate. All microarray data are available through Gene Expression Omnibus (Series accession numbers: GSE32891).
In silico functional analysis of the significant miRNAs. To identify a list of target genes of the miRNAs of interest, we used TargetScan for gene predictions and pathway analysis. Our studies also considered predictions and experimentally validated miRNA targets in miRecords databases. The top 10% of the most reliably predicted target genes of the 10 urinary miRNAs were selected according to the p values given in the database. The selected target genes were then input into Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Inc., Redwood City, CA). Ingenuity Core Analysis and Knowledge Base were used as the reference set. IPA interpreted the genes in the context of biological processes, pathways, and molecular networks and defined the most relevant biological functions related to these miRNAs.
RESULTS

Clinical Chemistry and Histopathological Examination
For the CCl 4 treatment, rats were treated with a single dose of 0 or 2000 mg/kg and then euthanized 24 h after dosing. Animals receiving CCl 4 showed a minimal to marked degree of centrilobular hepatocellular degeneration, necrosis, cellular infiltration, and cytoplasmic vacuolization. The kidneys appeared normal by histopathological evaluation. CCl 4 treatment induced significant increases of serum ALT, AST, and ALP (Table 1) . These increases in serum markers of liver injury were in agreement with previous studies (Maziasz et al., 1991; Zidek et al., 2007) .
As part of a previous study (Yang et al., 2011) , rats were treated with a single dose of 0, 100, or 1250 mg/kg of APAP by oral gavage and then euthanized 6 or 24 h after dosing. Only the 24-h time point samples from the high-dose animals (1250 mg/kg) were used in the current study. All high-dose APAP-treated rats (n ¼ 7) exhibited centrilobular glycogen depletion and four of them exhibited minimal to moderate centrilobular necrosis (Supplementary table 1) . The kidneys appeared normal by histopathological evaluation. The ALT and AST responses displayed high interanimal variability with some animals exhibiting very high levels and others having levels similar to controls (Supplementary table 1) .
For the PCN treatment, rats were treated with a single dose of 0 or 2400 mg/kg and then euthanized 24 h after dosing. PCN is not considered a liver toxicant but it can cause other adverse effects at high doses (Dunnick and Elwell, 1989) . As expected, livers from rats receiving PCN (2400 mg/kg) were morphologically normal and clinical chemistry parameters (e.g., ALT, AST, and ALP) were not significantly altered. The kidneys also appeared normal by histopathological evaluation. As part of this study, an additional group of animals were administered URINARY miRNA IN RATS AS LIVER TOXICITY BIOMARKER PCN for 14 consecutive days. These animals exhibited melena and loose stools, most likely due to significant alteration of the intestinal flora, which indicated that the dose selected for the study was the maximum tolerated dose.
Data Normalization and miRNAs Changes
Three internal control ''housekeeping'' miRNAs (miR-193, miR-323*, and miR-675) were used for normalization using the mean of multiple Ct values. As discussed in our previous paper (Yang et al., 2011) , other normalization procedures typically used for tissues (e.g., global normalization or normalization against noncoding small nuclear RNAs such as U6) were not suitable for normalization in urine. The software geNorm was used to validate that these three miRNAs were the most reliable internal controls (Vandesompele et al., 2002) .
Equal amounts of total urine RNA (300 ng) from each rat were used in the PCR arrays. The selected analysis filter (t-test analysis p < 0.01, fold change > 2) identified 28 and 44 miRNAs that were significantly increased after CCl 4 or APAP exposure, respectively. The 28 miRNAs increased after CCl 4 are presented in Table 2 . Several of the miRNAs had very large increases with 22.9-fold and 14.8-fold increases for miR-484 and miRNA-370. The 44 miRNAs increased after APAP were presented in our previous paper and are provided for reference in Supplementary table 2. Similar to CCl 4 , several of the miRNAs had very large increases in the urine following APAP treatment. For data derived from the CCl 4 study, cluster analysis of the 28 significantly changed miRNAs revealed two major clusters: control animals versus CCl 4 -treated animals (Fig. 1) . For APAP, cluster analysis of the 44 significantly changed miRNAs was presented in our previous paper and revealed two major clusters: control animals versus APAPtreated animals (Supplementary fig. 1 ). In contrast to the CCl 4 and APAP results, PCN caused a significant decrease in 27 urinary miRNAs (data not shown).
In order to assess if the liver was the source of the increased urinary miRNAs, miRNA levels were measured in the liver of the APAP-and CCl 4 -treated rats. For APAP, for all 44 miRNAs that were increased in the urine, a corresponding decrease in the liver was observed (Supplementary table 2 ). To further demonstrate the opposite direction changes between liver and urine, miR-291a-5p levels from APAP-treated rats were plotted by animal. As shown in Figure 2A , all APAPtreated animals showed increased miR-291a-5p levels in the urine with a corresponding decrease in the liver. Liver miR291a-5p expression in the APAP group also correlated well with histopathology scores for centrilobular necrosis (Fig. 2B , R 2 ¼ 0.71). For CCl 4 , for the 28 miRNAs that were increased in the urine, only one miRNA (miR-291a-5p) had a corresponding decrease in the liver (Supplementary table 3) . For the other 27 miRNAs, 6 were increased, with the remainder being unchanged (Supplementary table 3) .
Urinary miRNAs Profiles Separate APAP and CCl 4 From PCN Treatment
We identified 10 increased urinary miRNAs (Fig. 3A ), which were in common between APAP and CCl 4 , for the classification of the hepatotoxicants. Clustering of the samples was performed with six groups of miRNA samples (APAP, CCl 4 , PCN-treated and their respective controls) using these 10 miRNAs. In the HCA, the animals were divided into two clearly separated branches: one branch containing the three controls and PCN-treated groups and the other containing the APAP-and CCl 4 -treated groups (Fig. 3B) . In addition, the APAP and CCl 4 samples were divided into two smaller groups by treatment. Interestingly, APAP high-dose-treated no. 2 and no. 7 samples, which exhibited more severe signs of liver toxicity based on dramatically increased serum ALT and moderate centrilobular liver necrosis, were clustered with the CCl 4 samples. The subclustering of the APAP-treated animals Note. Rats were administered a single oral gavage dose of CCl 4 or vehicle control (corn oil), and blood and histopathology samples were collected~24 h after dosing. Histopathology lesions were scored on a 5-point scale (0 ¼ normal, 1 ¼ minimal, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ marked).
*Differences between groups were considered significant at p < 0.05. Serum ALT and AST values were log-transformed prior to statistical analysis. Histopathology scores were not statistically analyzed.
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is likely due to the response variations observed within this group as exemplified by serum ALT and AST and histopathological indices (Supplementary table 1) . The PCA plot for control, APAP, CCl 4 , and PCN samples suggested that the APAP and CCl 4 animals can be clearly separated from the PCN and control rats along PC1, which accounted for 85.8% of the variability (Supplementary fig. 2 ).
The fold changes of the 10 hepatotoxicant common urinary miRNAs from APAP, CCl 4 , and PCN samples were plotted together to illustrate the opposite trends between the hepatotoxicants and nonhepatotoxicant and the similarity in changes between APAP and CCl 4 (Fig. 4) . All 10 urinary miRNA levels were increased in the hepatotoxicant-treated groups; however, the same miRNAs showed slight decreases in the PCN group. The distinct grouping of the hepatotoxicant samples shows that the patterns of the APAP and CCl 4 samples were clearly different from the PCN and control samples.
Urine miRNAs Show Promise as Biomarkers for Liver Injury
TargetScan (Lewis et al., 2003) was used for the identification of potential target genes regulated by the 10 shared and significantly altered miRNAs in the hepatotoxicanttreated groups. The top 10% of the predicted targets (158 genes) for the 10 significant miRNAs were input into IPA software and the related functions and pathways were determined and are provided in Figure 5 . Cell death, cell-tocell signaling, and drug metabolism were the top three ranked biological networks potentially affected by the 10 miRNA species that had increased levels in the urine.
To identify whether the changes of urinary miRNA reflects gene expression alterations in the liver, we performed whole rno-miR-465 3.9 ± 2.1 16.3 ± 6.7 4.1 rno-miR-21* 1.9 ± 0.7 5.1 ± 1.2 2.6 rno-miR-504 7.5 ± 3.5 23.1 ± 9.8 3.1 rno-miR-127 3.6 ± 1.5 10.8 ± 3.8 3.0 rno-miR-346
11.4 ±6.3 24.8 ± 6.4 2.2 rno-miR-185
1.2 ± 0.5 2.9 ± 1.0 2.4 a rno-miR-877 46.5 ± 51.6 318.5 ± 214.3 6.8 rno-miR-182
6.6 ± 6.2 48.3 ± 27.4 7.4 rno-miR-326
1.7 ± 1.5 6.1 ± 3.0 3.6 rno-miR-484 6.0 ± 3.0 136.7 ± 112.4 22.9 a rno-miR-30c 22.5 ± 19.3 111.0 ± 63.9 4.9 rno-miR-759
1.0 ± 0.0 6.2 ± 3.6 6.2 rno-let-7e* 1.0 ± 0.0 2.5 ± 1.1 2.5 rno-miR-30b-5p
23.4 ± 18.1 88.2 ± 49.1 3.8 rno-miR-20b-3p
9.3 ± 9.5 39.0 ± 21.9 4.2 a rno-miR-433 7.5 ± 9.1 38.3 ± 24.9 5.1 a rno-miR-742 4.8 ± 4.6 22.3 ± 11.4 4.7 rno-miR-300-3p
1.0 ± 0.0 3.4 ± 2.2 3.4 rno-miR-878
1.8 ± 1.0 6.6 ± 4.2 3.7
Note. The relative miRNA levels were calculated by 2 ÀDCt , normalized to three housekeeping miRNAs (miR-193, miR-323*, and miR-675) , and presented as mean ± SD, p < 0.05. 
URINARY miRNA IN RATS AS LIVER TOXICITY BIOMARKER
genome microarray analysis on the same animals. RNA was prepared from livers of control and APAP-or CCl 4 -treated rats and subjected to microarray analysis. The significantly regulated gene lists were selected by the P value < 0.05 and fold change ! 1.5. It was of particular interest to discover which putative target genes of the 10 significant urinary miRNAs overlapped with the significantly changed genes from the liver microarray analysis for APAP and CCl 4 . The putative gene targets (1421 genes) were compared with the gene list shared and significantly changed in the hepatotoxicant-treated groups (1554 genes). Eight of these putative target genes were found to be significantly altered in the liver of APAP-and CCl 4 -treated animals. The liver mRNA results are shown in Figure 6 . Note that the direction of change was the same for APAP and CCl 4 for the eight common transcripts, with one downregulated and seven upregulated.
DISCUSSION
To investigate the biological and mechanistic processes of chemical-induced organ injury on human health, new sensitive, informative, and reproducible biomarkers are needed (Stine and Lewis, 2011) . Over the past decade, investigators have developed microarray profiling of gene expression alterations after xenobiotic exposure, often referred to as ''toxicogenomics,'' into a powerful tool for investigating the biological processes of chemical-induced organ injury (Mendrick, 2011; Mendrick and Schnackenberg, 2009) . Previous reports have demonstrated that exposure to different toxicants could be classified in rodent models by gene expression microarray profiling of target tissues and blood (Bushel et al., 2007; Lobenhofer et al., 2008) . Gene expression changes may be more sensitive biomarkers of potential adverse effects than traditional measurements of organ injury (Heinloth et al., 2004) , and many studies have demonstrated the utility of using microarrays as a tool for gene expression profiling to predict the liver toxicity induced by various hepatotoxicants (Zidek et al., 2007) . Our work is the first demonstration of the usefulness of urinary miRNAs as indicators of liver necrosis across several hepatotoxicants.
miRNAs are a newly discovered group of noncoding RNA and meet many of the ideal biomarker criteria of high specificity, sensitivity, and accuracy (Etheridge et al., 2011; Yokoi and Nakajima, 2011) . The discovery of circulating miRNAs in the urine and blood has created a new approach for the discovery of noninvasive biomarkers of organ injury (Laterza et al., 2009; Weber et al., 2010) . Although the full realization of miRNA's functional response to chemical toxicants has yet to be established, there is little doubt that miRNAs are important in the cellular and in vivo responses to xenobiotics (Taylor and Gant, 2008) . Previous studies have found tissue-specific miRNA in the blood as suggested they might serve as potential biomarkers for detecting APAP-or viral-related liver injury (Wang et al., 2009; Zhang et al., 2010) . However, there are still open questions regarding the utility of circulating miRNAs in reflecting organ injury and classifying that injury between various agents.
A major finding of this study is that common urinary miRNAs are identified between APAP-and CCl 4 -treated rats, and the miRNA expression profile is able to distinguish the patterns of the responses to hepatotoxicant versus a nonhepatotoxicant and controls. Although a larger number of chemicals will need to be tested, the findings in this study suggest that urinary miRNA might be a more specific and consistent biomarker of chemical-induced liver injury than the current serum ALT and AST tests. Although the full functional and regulatory mechanisms of the 10 common miRNA are unknown, the possible target genes of these miRNAs are related to cell death, cell-to-cell signaling, and drug metabolism. Furthermore, the possible target genes of the urinary miRNAs have some overlap with the significantly changed   FIG. 2 . Urinary miRNA correlated with APAP-induced liver miRNA changes. (A) miR-291a-5p is decreased in the liver of each animal (green bars) upon APAP (1250 mg/kg) exposure, whereas the urinary level of the same miRNA is increased (red bars). The fold changes are displayed on a log 2 scale. (B) Correlation between the liver miR-291a-5p levels and histopathology centrilobular necrosis scores in APAP-treated rats. Liver centrilobular necrosis was scored on a 5-point scale (0 ¼ normal, 1 ¼ minimal, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ marked). 340 genes from APAP-and CCl 4 -treated liver tissues. For the eight hepatic genes that overlapped with the possible target miRNA genes, seven of them were upregulated (Fig. 6) . This is consistent with the idea that miRNA leaks from hepatotoxicant-injured cells into the blood and then into the urine. Decreased hepatic miRNA would lead to increased hepatic expression of their target genes. This appears likely for APAP because the urinary miRNAs that were increased had corresponding hepatic miRNA decreases; however, the results for CCl 4 were equivocal because only one hepatic miRNA was significantly decreased. For the one gene that was downregulated (Cav2), it is possible that miRNA acts as an enhancer of gene expression for that specific gene because miRNA has been shown to activate gene expression, although this occurs less often than gene repression (Yokoi and Nakajima, 2011) . This study, therefore, has revealed a novel approach of using cell-free circulating miRNAs as biomarkers to detect chemicalinduced liver injury.
In this study, we have demonstrated that the levels of 10 common miRNA levels are increased in the hepatotoxicant-treated urine samples. A previous study observed reciprocal changes between plasma and liver tissue miRNA after APAP exposure indicating that cellular damage in the liver causes the transport or release of cellular miRNA into the blood (Wang et al., 2009) . For APAP, we observed a similar reciprocal change in urinary and hepatic miRNAs suggesting that the increased miRNAs in the urine are released from injured liver through either an active or passive (e.g., cellular necrosis) process. For CCl 4 , the results are not as clear because only one increased urinary miRNA had a reciprocal decrease in the liver. It is possible that CCl 4 causes hepatic miRNA release via different mechanisms than APAP. miRNA release from the liver is likely to be affected by a variety of different mechanisms. First, miRNA levels of the liver cells could be altered leading to changes in the amount of miRNA released via normal processes. Second, normal miRNA release from cells via microvesicles, exosomes, or protein-bound complexes could be altered. Third, cell injury and death (e.g., necrosis or apoptosis) could lead to gross leakage of miRNA. All of these processes could affect the amount of miRNA released from the liver into URINARY miRNA IN RATS AS LIVER TOXICITY BIOMARKER the plasma and subsequently into other cell-free body fluids, such as urine. If APAP and CCl 4 differentially affect these pathways, reciprocal changes in urine and liver miRNA levels may or may not be observed. The reasons for the slightly decreased miRNA levels in PCN-treated animals are not known. However, it may reflect changes in the specific miRNA packaging and transportation systems , which actively export miRNAs for cell-cell communication. These changes may occur in response to altered microflora from the antibiotic treatment and the resulting shift in the body's state of homeostasis.
Computational prediction of miRNA target genes is challenging because the pairing between miRNA and the target sequence can occur with partial complementation. The most commonly used tools, including TargetScan, miRanda, and PicTar, search for miRNA targets exclusively in mRNA 3#-UTR; however, increasing evidence demonstrates that targeting can also be mediated through sites other than 3#-UTR (Thomson et al., 2011) . Therefore, the presented results are tentative; however, they do provide insight into methods for possibly assessing the functional relevance of miRNA changes in cell-free body fluids. Since recognition is based on a short sequence, each miRNA can regulate many different target genes. Here, we used the TargetScan to predict the target genes of the 10 common miRNAs. When these genes were entered into the pathway analysis program, the target genes were predicted to be associated with necrosis, breakdown of tissue integrity, and xenobiotic metabolism, which all play a role in APAP and CCl 4 hepatotoxicity. Some gene targets of the 10 miRNAs have been validated in previous reports and their functions may reveal the biological responses to the hepatotoxicants. For example, miR-296, which had ! 3.9-fold increase in the urine of APAP-and CCl 4 -treated rats (Fig. 4) , was found to regulates hepatocyte growth factor receptor overexpression (Würdinger et al., 2008) . The changes of miR-296 may relate to blood vessel development as well as the disease-related processes including tumor growth, wound healing, and restoring blood flow to tissues after injury (Vaira et al., forthcoming) . miR-433, which increased ! 5.1-fold in the urine (Fig. 4) , has been reported to play important roles in development, metabolism, and carcinogenesis (Luo et al., 2009; Song and Wang, 2008) . Recent studies suggested that miR-185, increased ! 2.4-fold in the urine (Fig. 4) , can induce cell cycle arrest (Takahashi et al., 2009) . Therefore, these 10 common miRNA might represent a toxicological response to the chemical-induced liver injury.
Our study has a few limitations. Changes in urinary miRNAs may not represent transrenal passage of the miRNAs from the blood into the urine and may simply represent changes in the kidney in response to the hepatotoxicants. APAP has been shown to affect the kidneys in some strains of rats at high doses (Bessems and Vermeulen, 2001 ). It appears unlikely that adverse effects on the kidney were the cause of the increased urinary miRNAs because histopathological analysis confirmed that the kidneys were unaffected by APAP, and the SpragueDawley strain of rat is resistant to APAP-induced kidney injury (Newton et al., 1983) . CCl 4 -treated rats showed no histopathological changes in the kidney although some reports do show it can induce nephrotoxicity in rats (Khan et al., 2009; Ozturk et al., 2003) . In addition, in a preliminary study of kidney ischemia, urinary miRNA levels increased but the profile did not overlap with either APAP or CCl 4 (data not shown). Measuring urinary miRNA levels and making correlations to hepatic gene expression changes are indirect because plasma miRNA levels were not measured. The main purpose of this study was to identify new biomarkers of hepatotoxicity, which appears promising based on the urinary miRNA results. A secondary purpose was to confirm the biological plausibility of the increased urinary miRNAs by probing gene expression changes to see if they correlated with the mechanisms of hepatotoxicity for these well-characterized toxicants. Although this analysis focused on those miRNA commonly altered by the two hepatotoxicants, as more compounds are assayed, a secondary focus will be the examination of chemical-or injury-specific patterns. As has been widely reported using toxicogenomics for the study of liver mRNA, patterns of changes overlap yet some genes show some specificity to injury type and to individual compounds. CCl 4 is known to induce fatty liver and others types of injury besides necrosis, and the results analyzed here do show some uniqueness to the miRNA changes observed with APAP or CCl 4 treatment. In clinical situations, a patient might be on many drugs before any sign of liver injury appears. Currently, there are not unique patterns of currently used biomarkers that distinguish the cause of injury, leaving the clinician with the option of removing one drug at a time to try and reverse the injury. In addition, biopsy of the liver to document the type of histological change is approached with caution due to morbidity and mortality concerns. Thus, if miRNA patterns in the urine reflect either histological patterns or specific offending agent, they offer even more utility than just providing more sensitive and specific biomarkers of overall liver injury. Commonality and uniqueness in response were both seen in this study (Fig. 3) .
In summary, acute administration of hepatotoxic chemicals resulted in changes of urinary miRNA levels. Comparing the APAP and CCl 4 samples with PCN controls revealed 10 common miRNA species with increased levels in the urine. The observation of the overlapping miRNA changes in response to two different hepatotoxicants indicates that urinary miRNA profiling may be useful as both biomarkers and for the classification of toxicants. Additional work is underway to test if these findings can be replicated for other classical or idiosyncratic hepatotoxicants. Furthermore, the overlap between the putative gene targets of the urinary miRNAs and significantly altered hepatic genes might improve our understanding and prediction of toxicology processes. Equally important may be the uniqueness of patterns but more compounds need to be assayed before any conclusion can be made.
SUPPLEMENTARY DATA
Supplementary data are available online at http:// toxsci.oxfordjournals.org/. 6 . Gene list shared between putative urinary miRNA targets and altered liver transcripts using whole genome microarray. The target genes of the 10 urinary miRNAs were computationally predicted by TargetScan and miRanda. Liver gene expression was measured using single color (Cy3) Agilent Whole Rat Genome 4 3 44 K microarrays. The liver mRNAs with p < 0.05 and an absolute value of fold change ! 1.5 were considered significantly altered transcripts.
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